BHCM
ANIP icon

Brevan Howard Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Brevan Howard Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$575K Sell
7,471
-14,766
-66% -$1.15M 0.01% 1216
2025
Q4 		$1.76M Buy
22,237
+10,037
+82% +$869K 0.02% 524
2025
Q3 		$1.12M Buy
+12,200
New +$995K 0.01% 843

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brevan Howard Capital Management's ANIP Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 66% in Q1 2026, selling an estimated $1.15M and leaving 7,471 shares worth $575K. The position accounts for 0.01% of the portfolio, ranked #1216.

Brevan Howard Capital Management first reported a position in ANIP in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.76M in Q4 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Brevan Howard Capital Management held 7,471 shares of ANI Pharmaceuticals worth $575K as of Q1 2026.
  • Brevan Howard Capital Management sold 14,766 ANI Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
  • ANI Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1216 holding.
  • Brevan Howard Capital Management first reported a position in ANI Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's ANI Pharmaceuticals position peaked at $1.76M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.